Open AccessDrug updates and approvals
Author(s) -
Cortney M. Mospan,
Geoffrey Mospan,
Emily Byland,
W Whitaker,
Linda Xiong,
Jordan Dunlap,
Katherine Canupp
Publication year - 2018
Publication title -
the nurse practitioner/the nurse practitioner
Language(s) - English
Resource type - Journals
eISSN - 1538-8662
pISSN - 0361-1817
DOI - 10.1097/01.npr.0000547548.63764.6b
Subject(s) - tenofovir alafenamide , pharmacology , medicine , drug , human immunodeficiency virus (hiv) , virology , viral load , antiretroviral therapy
In 2018, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy); doxylamine succinate and pyridoxine hydrochloride (Bonjesta); erenumab-aooe (Aimovig); lofexidine hydrochloride (Lucemyra); tezacaftor and ivacaftor (Symdeko); and tildrakizumab-asmn (Ilumya).